Protocol Ledger

NCT06873815 · Phase II · RECRUITING

A Study of Fluorescein Sodium in People Undergoing Vulvectomy for Extramammary Paget's Disease (EMPD)

Interventional Phase II clinical trial protocol NCT06873815 sponsored by Memorial Sloan Kettering Cancer Center in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-07 Enrollment: 27 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06873815
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)27 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06873815
Protocol FieldVerified Registry Value
NCT IdentifierNCT06873815
Consolidated Lead SponsorMemorial Sloan Kettering Cancer Center
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment27 participants (ESTIMATED)
Registered Start Date2025-03-07
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Memorial Sloan Kettering Cancer Center across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI